Intervacc AB (FRA:2E9) Notes Receivable: €0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:2E9 Intervacc AB FRA:2E9
60 GF Score
Price €0.08
GF Value €0.08
! 1 Warning Sign
View Full Analysis

What is Intervacc AB Notes Receivable?

Intervacc AB FRA:2E9 -3.18% 60 Notes Receivable is €0.00 Mil as of Jun. 2026. GuruFocus rates FRA:2E9 with a GF Score™ of 60/100 and a GF Value™ of €0.08. The stock has 1 warning sign investors should review.

Intervacc AB's Notes Receivable for the quarter that ended in Jun. 2026 was €0.00 Mil.

Intervacc AB Notes Receivable Historical Data

* Premium members only.

The historical data trend for Intervacc AB's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Intervacc AB Notes Receivable Chart

Intervacc AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Intervacc AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:2E9
60GF Score
Intervacc AB FRA:2E9
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Intervacc AB Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of €0.00 Mil mean?
Intervacc AB (FRA:2E9) has a Notes Receivable of €0.00 Mil as of Jun. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Intervacc AB and its competitors.
Is Intervacc AB's Notes Receivable too high?
Intervacc AB's current Notes Receivable is €0.00 Mil. Overall, Intervacc AB has a GF Score™ of 60/100, reflecting its overall financial health beyond just this single metric.
How does Intervacc AB's Notes Receivable compare to VRTX and REGN?
Intervacc AB's Notes Receivable of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Intervacc AB and its competitors. Intervacc AB's current Notes Receivable is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intervacc AB stock overvalued right now?
Intervacc AB (FRA:2E9) has a current Notes Receivable of €0.00 Mil. The stock's GF Value™ is €0.08, compared to a current price of €0.08 — trading 1% below its estimated fair value. The current Notes Receivable is €0.00 Mil. Intervacc AB's overall GF Score™ is 60/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Intervacc AB (FRA:2E9), the current Notes Receivable is €0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Intervacc AB (FRA:2E9) Overvalued in 2026?

Based on GuruFocus' analysis, Intervacc AB stock appears to be undervalued. The current stock price of €0.08 is trading 1% below its estimated GF Value™ of €0.08.

Key valuation signals for FRA:2E9:

  • Notes Receivable: €0.00 Mil
  • GF Value™: €0.08 vs. price of €0.08 (1% below fair value)
  • GF Score™: 60/100 with 1 warning sign

No single metric tells the full story. See the FRA:2E9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Intervacc AB Business Description

Other Exchanges IVACC:Sweden
Address Vastertorpsvagen 135, Hagersten, Stockholm, SWE, S-129 44
Intervacc AB is a biotechnology company. It develops new vaccines based on recombinant proteins to meet the increasing need for effective vaccines in animal health care. The company through its subsidiary focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses on the Swedish market.
60GF Score

Get the complete analysis for FRA:2E9

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.08
Price
€0.08
GF Value